Cancer treatment has changed more in the last decade than it did in the previous fifty years. Among the most promising shifts has been the rise of CAR T-cell therapy — a treatment approach that reprograms a patient’s own immune cells to hunt down and destroy cancer. Within this evolving landscape, few stories capture the highs and lows of modern biotech quite like the journey of 2seventy bio.
Founded as a spinoff from Bluebird Bio in late 2021, this Cambridge, Massachusetts-based company set out with an ambitious goal: to develop and commercialize breakthrough cell therapies for cancer. The name itself was a statement of intent. It was inspired by 270 miles per hour, described as the maximum speed at which the human brain translates thought into action. At 2seventy bio, the idea was to think smarter and faster than cancer itself.
But ambition alone does not guarantee survival in the pharmaceutical industry. Over the course of roughly four years, the company navigated a turbulent biotech market, underwent painful restructuring, shed the majority of its pipeline, and ultimately sold itself to Bristol Myers Squibb in a deal worth approximately $286 million. What remains is Abecma, a groundbreaking CAR T-cell therapy that continues to help thousands of patients fighting multiple myeloma around the world.
This article tells the full story — from how the company was created, to the therapy that defined it, to the financial pressures that reshaped it, and what its journey means for the broader biotech industry.
How a Biotech Pioneer Decided to Split in Two
To understand the origins of this company, you have to go back to Bluebird Bio. Founded in the early 1990s as Genetix Pharmaceuticals, Bluebird grew into one of the most closely watched gene therapy companies of the 2010s. It went public in 2013 and built a dual pipeline: gene therapies for rare diseases like sickle cell disease and beta thalassemia on one side, and oncology cell therapies on the other.
By 2021, Bluebird’s leadership had come to a pivotal conclusion. They believed that operating two fundamentally different businesses under one roof was holding both back. Gene therapy for rare diseases and cell therapy for cancer required different regulatory strategies, different commercial models, and different types of investor attention. The solution, in their view, was a clean split.
In November 2021, Bluebird completed the corporate spinoff of its oncology operations into a new, independently traded public company — 2seventy bio. Nick Leschly, who had led Bluebird for years, crossed over to serve as the new company’s first CEO, adopting the internal title of “chief kairos officer,” a nod to the Greek word for a decisive, opportune moment.
The newly independent company launched with meaningful financial backing. It had significant cash reserves, a pipeline of cell therapy programs, and — most importantly — an already-approved product generating real revenue. That product was Abecma, a CAR T-cell therapy for multiple myeloma developed in partnership with Bristol Myers Squibb.
The early pipeline also included collaborations with Regeneron Pharmaceuticals, focused on new cell therapies for cancer, and a partnership with JW Therapeutics targeting solid tumors and autoimmune diseases. On paper, the company looked well-positioned. But the timing of the spinoff coincided with a broader downturn in biotech funding. Capital was drying up, investor sentiment was cooling, and small-cap biotechs faced mounting pressure to prove their worth quickly.
Abecma — The CAR T-Cell Therapy That Defined the Company
At the heart of everything 2seventy bio did was a single therapy: Abecma, known by its scientific name idecabtagene vicleucel, or ide-cel. It was the first BCMA-directed CAR T-cell therapy ever approved by the FDA for multiple myeloma, and it remains one of the most significant advances in treating this disease.
How Abecma works: The treatment begins by collecting a patient’s own T-cells through a process called leukapheresis. Those cells are then sent to a manufacturing facility where they are genetically modified using a lentiviral vector. This modification programs the T-cells to express a chimeric antigen receptor — a synthetic protein — that targets B-cell maturation antigen (BCMA), a protein found on the surface of myeloma cells. Once the modified cells are infused back into the patient, they seek out and attack the cancer.
It is a deeply personalized treatment. Every dose is custom-made for the individual patient, which is part of what makes it both powerful and logistically complex.
Key approval milestones: The FDA first approved Abecma in March 2021 for adults with relapsed or refractory multiple myeloma who had already received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. The approval was based on the KarMMa Phase II trial, which showed a 73 percent overall response rate and a 33 percent complete response rate at a median follow-up of roughly 13 months.
Then, in April 2024, the FDA granted a supplemental approval expanding the label to patients who had received two or more prior lines of therapy — a much larger patient population. This decision was supported by data from the KarMMa-3 Phase III trial, which demonstrated a progression-free survival of approximately 13 months in the Abecma arm compared to just 4 months for patients receiving standard regimens. The European Commission also approved the expanded indication, making Abecma the first CAR T-cell therapy authorized in the EU for use in earlier lines of multiple myeloma treatment.
Why it matters: Multiple myeloma is the second most common blood cancer in the world. While it remains incurable, therapies like Abecma have meaningfully extended survival for patients who had run out of standard options. For many of these individuals, it represented not just another treatment, but a genuinely new category of medicine.
Abecma generated $406 million in global sales for Bristol Myers Squibb in 2024, growing to approximately $427 million in 2025. Under the profit-sharing arrangement, 2seventy bio received half of U.S. commercial profits — the revenue stream that kept the company financially viable throughout its turbulent independent years.
The Financial and Operational Struggles of 2Seventy Bio
Despite having a commercially approved product, independence proved far more difficult than anyone had predicted. The biotech market deterioration that began in late 2021 continued to worsen, and the company found itself burning cash faster than it could generate revenue.
The September 2023 restructuring marked a turning point. The company announced a 40 percent reduction in its workforce — a painful move that affected dozens of employees who had been part of the original Bluebird team. Combined with related cost-cutting measures, the restructuring was projected to save more than $130 million over 2024 and 2025. But the cuts went far beyond headcount.
The company also made the difficult decision to scale back its pipeline. Programs like bbT369 for non-Hodgkin lymphoma and SC-DARIC33 for acute myeloid leukemia were gated pending further clinical data. The AML program had already run into serious trouble — the FDA had placed a clinical hold on the CD33-targeted CAR T trial after a patient died during an early-phase study conducted at Seattle Children’s. While investigators had already paused enrollment following the death, the formal FDA hold underscored the risks inherent in developing cutting-edge cell therapies.
Net losses for 2023 reached $217.6 million against just $100.4 million in revenue. Even with the restructuring savings, the financial math was challenging.
Leadership changes compounded the uncertainty. Nick Leschly, the founding CEO, announced his intention to step down. Chip Baird, who had been serving as CFO, was promoted first to Chief Operating Officer and then to CEO. Leschly transitioned to the role of board chairman.
Under Baird’s leadership, the company made the strategic decision to shed nearly all of its development pipeline and focus exclusively on Abecma. R&D programs were transitioned to Regeneron and Novo Nordisk, eliminating significant research expenditures. A further 14 percent workforce reduction followed in January 2024 — about 30 additional jobs.
By the end of 2024, net losses had narrowed considerably to $57.2 million, and the company held approximately $183.6 million in cash, cash equivalents, and marketable securities. 2seventy bio had successfully stabilized its finances, but at the cost of becoming a single-product company with limited ability to grow on its own.
The Competitive Landscape That Shaped the Outcome
The challenges facing the company were not only internal. The competitive environment for CAR T-cell therapies in multiple myeloma was intensifying rapidly, and Abecma found itself fighting for market share against a formidable rival.
Carvykti (ciltacabtagene autoleucel), developed by Johnson and Johnson in partnership with Legend Biotech, had emerged as the dominant force in the space. Carvykti generated nearly $1 billion in sales in 2024 and continued to gain ground. It benefited from strong clinical data, efficient manufacturing scale-up, and aggressive commercial execution. Many treating physicians came to view Carvykti as the preferred option, particularly as it demonstrated compelling long-term outcomes in clinical trials.
Adding to the pressure, Gilead Sciences and Arcellx were advancing another multiple myeloma cell therapy toward potential approval, threatening to crowd an already competitive market further.
Abecma’s own commercial launch had been initially hampered by supply constraints — a common challenge for autologous cell therapies that require patient-specific manufacturing. Unlike traditional drugs that can be produced in bulk at a factory, each dose of a CAR T treatment starts with a single patient’s blood draw and goes through weeks of specialized processing. Delays in turnaround times frustrated physicians and patients alike. By the time supply had normalized, Carvykti had already established a strong foothold with oncologists and treatment centers.
The broader market, however, remained encouraging. The global CAR T-cell therapy market was valued at roughly $6 billion in 2025, with the multiple myeloma segment accounting for more than 30 percent of that total. Projections estimate this market could reach anywhere between $15 billion and $22 billion by the mid-2030s, driven by expanding indications, improved manufacturing processes, and growing physician familiarity with these treatments. Research from Spherix Global Insights published in early 2026 found that nearly three-quarters of surveyed oncologists and hematologists agreed that CAR T-cell therapies would eventually become a first-line standard of care for multiple myeloma — a remarkable shift from even a few years earlier, when most physicians viewed cell therapies as a last resort for patients who had failed everything else.
The cost of treatment also remains a significant factor in the landscape. A single CAR T-cell infusion can cost several hundred thousand dollars before factoring in hospitalization, monitoring, and management of side effects like cytokine release syndrome. These economics create a tension between clinical promise and healthcare system sustainability that every company in the space must navigate.
The question for 2seventy bio was whether a single-product company with a second-place therapy could survive long enough to benefit from this expansion. The answer, ultimately, was no — at least not as an independent entity.
Bristol Myers Squibb’s Acquisition of 2Seventy Bio
On March 10, 2025, the long-rumored deal finally became official. Bristol Myers Squibb announced a definitive merger agreement to acquire all outstanding shares of 2seventy bio at $5.00 per share in an all-cash transaction. The deal valued the company’s total equity at approximately $286 million, or about $102 million net of estimated cash.
The offer represented an 88 percent premium over the closing share price of $2.66 on March 7, 2025. But in the broader context, it was a sobering number. The company’s market capitalization had once been several times higher, and many early investors in the stock absorbed significant losses.
The strategic rationale for BMS was straightforward. By acquiring the company outright, Bristol Myers would gain full ownership of Abecma and eliminate the profit-sharing arrangement that had cost it $43 million in U.S. commercial payments in 2024 alone. Over time, the acquisition would allow BMS to capture all future Abecma revenue — a product that generated $427 million globally in 2025 and continued to grow modestly.
Chip Baird, in his final public statement as CEO, called the deal “the culmination of the journey for 2seventy bio.” He expressed gratitude to current and former employees and to the broader community of patients, scientists, and partners who had helped turn cell and gene therapy from a complicated idea into a reality for patients.
The acquisition closed quickly. BMS launched a tender offer on April 14, 2025. The antitrust waiting period under the Hart-Scott-Rodino Act expired on May 2. By the time the tender offer expired on May 12, approximately 81.8 percent of outstanding shares had been validly tendered. BMS accepted all tendered shares on May 13 and completed a second-step merger the same day, making the company a wholly-owned subsidiary of Bristol Myers Squibb.
Following the merger, TSVT shares were delisted from Nasdaq. All prior board members resigned, new leadership was installed under BMS, and the independent chapter of this company came to a close.
What This Story Means for the Biotech Industry
The rise and acquisition of 2seventy bio is more than a single company narrative. It holds broader lessons for the entire cell and gene therapy sector.
The spinoff model has real risks. When Bluebird Bio decided to split, the logic seemed sound — let each business pursue its own strategy with dedicated resources. But both halves ultimately struggled. Bluebird itself was acquired by Carlyle Group and SK Capital Partners in 2025 after years of financial difficulties and workforce reductions, subsequently rebranding as Genetix Biotherapeutics. The parallel fates of parent and spinoff suggest that splitting a company during a market downturn can leave both entities undercapitalized and vulnerable. Investors, employees, and partners may be better served by restructuring within a single corporate shell rather than dividing resources between two companies that each lack the scale to weather adversity alone.
Single-product dependency is dangerous. While the strategic pivot to focus exclusively on Abecma helped stabilize the company’s finances, it also eliminated any path to organic growth. Without a diversified pipeline, the company had no way to generate independent value beyond what Abecma could provide — and with BMS already owning the other half of the commercial arrangement, a buyout became the logical endpoint. This is a recurring pattern in small biotech: a company narrows its focus to survive, only to discover that the narrowed focus makes it an acquisition target rather than a sustainable business.
Timing and market conditions matter as much as science. The biotech funding environment that existed in 2019 and 2020 — when capital was cheap and investor appetite for cell therapy stories was enormous — had evaporated by the time the company began operating independently. Had the spinoff occurred two years earlier, the company might have been able to raise capital at far higher valuations and fund its pipeline through clinical milestones. Instead, it launched into headwinds that never really subsided.
The therapy itself lives on. This is the most important point. Even though the independent company no longer exists, Abecma continues to treat thousands of multiple myeloma patients worldwide. Under BMS’s ownership, the therapy may benefit from greater manufacturing capacity, expanded global distribution, and potential further label expansions. The science and the patients it serves were never defined by the corporate structure around them.
The CAR T-cell therapy field is still early in its evolution. Treatments that were once reserved for patients who had exhausted all other options are now moving into earlier lines of therapy. The foundational work that began at this company — the clinical trials, the manufacturing processes, the regulatory groundwork — contributed meaningfully to that progress.
Conclusion
The story of 2seventy bio reads like a case study in modern biotech: bold ambition, genuine scientific achievement, harsh financial realities, and an outcome that was neither a fairy tale nor a failure. The company was born from one of the most respected names in gene therapy, built its identity around a transformative cancer treatment, fought through market downturns and competitive pressures, and ultimately found its home within a larger pharmaceutical company better equipped to carry the mission forward.
For the hundreds of employees who worked there, many of whom had been part of the original Bluebird Bio team, the closure of the independent company marked the end of a chapter they had poured years of effort into building. Their contributions to the science of cell therapy, however, extend well beyond any single corporate entity. The clinical trials they ran, the manufacturing processes they refined, and the regulatory pathways they helped establish created a foundation that the entire industry now builds upon.
For patients living with multiple myeloma, the corporate details matter far less than the treatment itself. Abecma remains available, its clinical evidence continues to grow, and the broader field of CAR T-cell therapy is expanding in ways that could eventually make these treatments a standard part of cancer care rather than a last resort. That is the real legacy here — not a ticker symbol or a merger press release, but a therapy that gives people more time.
Frequently Asked Questions
1. What is 2seventy bio? It was a Cambridge, Massachusetts-based immuno-oncology cell therapy company focused on developing and commercializing breakthrough treatments for cancer. Spun out of Bluebird Bio in November 2021, the company centered its work on Abecma, a CAR T-cell therapy for multiple myeloma, before being acquired by Bristol Myers Squibb in May 2025.
2. Why is it called 2seventy bio? The name comes from 270 miles per hour, which the company described as the maximum speed at which the human brain translates thought into physical action. It symbolized the company’s urgency to outpace cancer and deliver treatments to patients as quickly as possible.
3. Is 2seventy bio still a company? Not as an independent entity. Bristol Myers Squibb completed the acquisition of 2seventy bio on May 13, 2025, making it a wholly-owned subsidiary. Its stock (TSVT) was delisted from the Nasdaq exchange, and the company’s former website now redirects to Bristol Myers Squibb.
4. Where was 2seventy bio headquartered? The company was headquartered at 60 Binney Street in Cambridge, Massachusetts. This location placed it in the heart of the greater Boston biotech corridor, one of the largest concentrations of pharmaceutical and biotech companies in the world.
5. What is the connection between 2seventy bio and Bluebird Bio? Bluebird Bio spun off its oncology cell therapy operations into 2seventy bio as a separate publicly traded company in November 2021. Bluebird retained its rare disease gene therapy business, while the new company took over the cancer-focused pipeline, including the commercially approved therapy Abecma.
6. Why did Bluebird Bio spin off 2seventy bio? Bluebird’s leadership believed that running a rare disease gene therapy business and a cancer cell therapy business under one roof created competing priorities. Separating them was intended to let each company pursue focused strategies with dedicated management, clearer capital allocation, and distinct investor messaging.
7. What happened to Bluebird Bio after the spinoff? Bluebird Bio continued to struggle with profitability and growing debt after the separation. In early 2025, the company agreed to be acquired by investment funds managed by The Carlyle Group and SK Capital Partners, after which it rebranded as Genetix Biotherapeutics.
8. What is Abecma and what does it treat? Abecma (idecabtagene vicleucel, or ide-cel) is a BCMA-directed CAR T-cell immunotherapy used to treat adults with relapsed or refractory multiple myeloma. It was the first FDA-approved CAR T-cell therapy for this disease and works by genetically modifying a patient’s own immune cells to recognize and attack myeloma cells.
9. When was Abecma approved by the FDA? The FDA first approved Abecma in March 2021 for patients who had received four or more prior lines of therapy. In April 2024, the agency expanded the approval to include patients after just two or more prior lines of treatment, based on data from the KarMMa-3 Phase III clinical trial.
10. How does Abecma work? A patient’s T-cells are collected through a blood draw, then genetically modified in a lab to express a chimeric antigen receptor targeting the BCMA protein on myeloma cells. Once infused back into the patient, these engineered cells seek out and destroy cancer cells throughout the body. Each dose is custom-made for the individual patient.
11. What are the side effects of Abecma? The most common side effects include fatigue, fever, chills, nausea, diarrhea, decreased appetite, headache, dizziness, confusion, trouble breathing, and irregular heartbeat. Abecma also carries serious risks including cytokine release syndrome, neurotoxicity, and prolonged low blood cell counts, which is why treatment must be administered at specially certified medical centers.
12. How much does Abecma cost? The list price for a single Abecma infusion runs into the hundreds of thousands of dollars. This does not include hospitalization, monitoring, pre-treatment chemotherapy, or management of side effects, which can add significantly to the total cost of care.
13. What is the difference between Abecma and Carvykti? Both are BCMA-directed CAR T-cell therapies for multiple myeloma, but they use different engineered cell constructs. Carvykti (ciltacabtagene autoleucel), developed by Johnson and Johnson and Legend Biotech, has captured a larger market share and generated higher sales. As of 2024, Carvykti is approved for use after just one prior line of therapy, while Abecma is approved after two or more.
14. What was the stock ticker for 2seventy bio? The company traded on the Nasdaq Global Select Market under the ticker symbol TSVT from November 2021 until its delisting in May 2025 following the completion of the Bristol Myers Squibb acquisition.
15. How much revenue did 2seventy bio generate? Revenue was primarily derived from the company’s profit-sharing arrangement with BMS for Abecma’s U.S. commercial sales. Total revenue was approximately $100.4 million in 2023 and $37.9 million in 2024 after the company restructured and changed its revenue recognition. Abecma itself generated $406 million in global sales through BMS in 2024.
16. Was 2seventy bio ever profitable? The company reported net losses throughout most of its independent existence, including $217.6 million in 2023 and $57.2 million in 2024. It briefly reached near-breakeven in late 2024 after aggressive cost-cutting and recorded a small net income of $0.5 million in the first quarter of 2025, just before the acquisition closed.
17. Why did 2seventy bio lay off employees? The company executed two major rounds of layoffs. In September 2023, it cut approximately 40 percent of its workforce as part of a restructuring to save over $130 million. In January 2024, an additional 14 percent was eliminated when the company pivoted to focus exclusively on Abecma and sold its R&D pipeline to Regeneron.
18. Who acquired 2seventy bio and for how much? Bristol Myers Squibb acquired the company in an all-cash deal valued at approximately $286 million in total equity, or about $102 million net of estimated cash. BMS paid $5.00 per share, representing an 88 percent premium over the stock’s closing price on March 7, 2025.
19. When did the BMS acquisition of 2seventy bio close? The tender offer launched on April 14, 2025, the antitrust waiting period expired on May 2, and the tender offer expired on May 12. BMS accepted all tendered shares on May 13, 2025, completing the merger and making the company a wholly-owned subsidiary the same day.
20. Why did Bristol Myers Squibb buy 2seventy bio? BMS wanted to consolidate full ownership of Abecma. Under the prior arrangement, the two companies split U.S. commercial profits equally, costing BMS $43 million in profit-sharing payments in 2024. Acquiring the company eliminated this expense and gave BMS total control over future Abecma development and commercialization.
21. Who was the CEO of 2seventy bio? The company had two CEOs during its independent run. Nick Leschly, who previously led Bluebird Bio, served as the founding CEO from November 2021 until stepping down in late 2023. Chip Baird, who had served as CFO and then COO, was appointed CEO in January 2024 and led the company through its acquisition by BMS.
22. Where is Chip Baird now after the 2seventy bio acquisition? Chip Baird became the president and CEO of Poplar Therapeutics, a newly launched biotech company focused on food allergy and atopic conditions. Poplar launched in January 2026 with a $50 million Series A financing led by Bain Capital, later extending the round to $95 million.
23. Is Abecma still available to patients after the acquisition? Yes. Abecma remains commercially available and continues to be prescribed for eligible multiple myeloma patients in the United States and other markets. Under BMS’s full ownership, the therapy generated $427 million in global sales in 2025, and the company has indicated its commitment to continuing Abecma’s development and distribution.
24. What does the 2seventy bio story mean for the biotech industry? It serves as a cautionary case study about the risks of biotech spinoffs during market downturns, the dangers of single-product dependency, and the difficulty small cell therapy companies face when competing against larger pharmaceutical rivals. At the same time, it demonstrates that a company’s scientific contribution can outlast its corporate existence — Abecma continues treating patients worldwide regardless of who owns it.
